Adams Katie, Higgins Lynne, Beazley Stella, Papagrigoriadis Savvas
Department of Academic Colorectal Surgery, King's College Hospital, 2nd Floor Hambledon Wing, Denmark Hill, London, SE5 9RS, UK.
Int J Colorectal Dis. 2015 Dec;30(12):1677-84. doi: 10.1007/s00384-015-2356-x. Epub 2015 Aug 30.
Current evidence suggests a survival benefit to post-operative surveillance following curative colorectal cancer resection; however, there is still no consensus on the optimal duration and form.
The objective is to prospectively audit outcomes of an intensive colorectal cancer follow-up scheme for time to recurrence and survival.
We used a surveillance protocol designed to incorporate regular clinical, biochemical, radiological and endoscopic measures at pre-defined intervals.
The setting was a Department of Colorectal Surgery in a Tertiary Academic Centre. Follow-up was led by specially trained colorectal nurses in conjunction with surgeons.
Consecutive patients who had undergone curative treatment for colorectal cancer were included in this study.
Outcomes were measured in terms of overall survival and disease recurrence.
There were 436 patients entered into follow-up, all treated with curative intent. Mean age 65.9 years (SD 12.9 years) and 240 male (55.0 %). Ninety-four patients (21.5 %) with stage I disease, 119 (27.3 %) stage IIa, 30 (6.9 %) stage IIb, 18 (4.1 %) stage IIIa, 78 (17.9 %) stage IIIb, 45 (10.4 %) stage IIIc and 52 (11.9 %) stage IV. Overall median survival was 37.5 months for all patients, (range 0.0-207.8 months). Ninety-two (21.1 %) cancer-related deaths were recorded during the course of the study. The overall 5-year actuarial cancer-related survival was 81.7 %. There was a 40.3 % 5-year actuarial survival was recorded in patients with 39 a recurrence, 57.7 % in patients treated with further curative 40 intent and 27.7 % in patients who received palliative treatment 41 (P < 0.001). Ninety-seven percent of recurrences were detected within 4 years of curative treatment.
This follow-up protocol confers an 81 % overall 5-year actuarial survival. Our study suggests that surveillance after curative resection can be limited to 4 years, which would lead to detection of over 97 % of all recurrences.
目前的证据表明,结直肠癌根治性切除术后进行术后监测对生存有益;然而,对于最佳监测持续时间和形式仍未达成共识。
前瞻性审核一项强化结直肠癌随访方案在复发时间和生存方面的结果。
我们采用了一种监测方案,该方案旨在按照预先确定的间隔纳入常规临床、生化、放射学和内镜检查措施。
研究地点为一家三级学术中心的结直肠外科。随访由经过专门培训的结直肠护士与外科医生共同进行。
本研究纳入了接受结直肠癌根治性治疗的连续患者。
结局通过总生存期和疾病复发情况进行衡量。
共有436例患者进入随访,均接受了根治性治疗。平均年龄65.9岁(标准差12.9岁),男性240例(55.0%)。94例(21.5%)为I期疾病,119例(27.3%)为IIa期,30例(6.9%)为IIb期,18例(4.1%)为IIIa期,78例(17.9%)为IIIb期,45例(10.4%)为IIIc期,52例(11.9%)为IV期。所有患者的总中位生存期为37.5个月(范围0.0 - 207.8个月)。在研究过程中记录了92例(21.1%)与癌症相关的死亡。5年癌症相关总生存率为81.7%。复发患者的5年精算生存率为40.3%,接受进一步根治性治疗的患者为57.7%,接受姑息治疗的患者为27.7%(P < 0.001)。97%的复发在根治性治疗后4年内被检测到。
该随访方案的5年总精算生存率为81%。我们的研究表明,根治性切除术后的监测可限制在4年,这将导致检测到超过97%的所有复发。